Refractory Colorectal Carcinoma: Clinical Trials

11 trials for Refractory Colorectal Carcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 active not recruiting, 3 completed, 2 withdrawn, 1 recruiting. 9 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 29Active not recruiting 3, Completed 3, Recruiting 1, Terminated 1, Withdrawn 1
Phase 13Active not recruiting 1, Completed 1, Withdrawn 1

Follow Refractory Colorectal Carcinoma: new trials by email Literature Review of Refractory Colorectal Carcinoma trials Research Report on Refractory Colorectal Carcinoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Biospecimen Collection, Computed Tomography, Devimistat - Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma
Phase 2RecruitingNorthwestern University942023-03-082023-03-10
Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
Guadecitabine, Nivolumab - Colorectal Adenocarcinoma, CpG Island Methylator Phenotype
Phase 1 / Phase 2WithdrawnUniversity of Southern California2020-01-302021-04-05
Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer
Fruquintinib Combined With TAS-102 - Colorectal Cancer, Metastatic Colorectal Cancer
WithdrawnFudan University2020-01-012026-08-03
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer
Oxaliplatin, Trifluridine and Tipiracil Hydrochloride - Metastatic Colorectal Carcinoma, Recurrent Colon Carcinoma
Phase 2Active not recruitingRutgers, The State University of New Jersey502019-02-122024-11-18
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
Best Practice, Laboratory Procedure, Quality-of-Life Assessment - Refractory Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8
Phase 2Active not recruitingM.D. Anderson Cancer Center1002019-01-292026-08-07
Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
Metformin, Nivolumab - Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma
Phase 2CompletedEmory University292019-01-152024-09-05
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
Autologous Tumor Infiltrating Lymphocytes MDA-TIL, Cyclophosphamide, Fludarabine - Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma
Phase 2TerminatedM.D. Anderson Cancer Center162018-10-162025-04-17
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
Anti-PD-L1/TGFbetaRII Fusion Protein M7824 - Colon Adenocarcinoma, High-Frequency Microsatellite Instability
Phase 1 / Phase 2CompletedM.D. Anderson Cancer Center42018-03-072024-11-27
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Atezolizumab, Bevacizumab, Capecitabine - Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma
Phase 2CompletedAcademic and Community Cancer Research United1332017-07-072024-08-23
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
Danvatirsen, Durvalumab - Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma
Phase 2Active not recruitingM.D. Anderson Cancer Center392017-03-022025-05-06
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Berzosertib, Biopsy Specimen, Biospecimen Collection - Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma
Phase 1Active not recruitingNational Cancer Institute (NCI)662016-07-222026-09-25

Narrower conditions

Colorectal Neoplasms (11)  ·  Lung Neoplasms (3)  ·  Pancreatic Neoplasms (3)  ·  Colonic Neoplasms (2)  ·  Neoplasm Metastasis (2)  ·  Ovarian Neoplasms (2)  ·  Adenocarcinoma of Lung (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Transitional Cell (1)  ·  Microsatellite Instability (1)  ·  Rectal Neoplasms (1)  ·  Small Cell Lung Carcinoma (1)  ·  Turcot syndrome (1)

Broader conditions

Colonic Diseases (11)  ·  Digestive System Diseases (11)  ·  Digestive System Neoplasms (11)  ·  Gastrointestinal Diseases (11)  ·  Gastrointestinal Neoplasms (11)  ·  Intestinal Diseases (11)  ·  Intestinal Neoplasms (11)  ·  Neoplasms (11)  ·  Neoplasms by Site (11)  ·  Rectal Diseases (11)  ·  Endocrine Gland Neoplasms (4)  ·  Endocrine System Diseases (4)  ·  Lung Diseases (3)  ·  Pancreatic Diseases (3)  ·  Respiratory Tract Diseases (3)

Interventions

trifluridine tipiracil drug combination (3)  ·  Disulfides (2)  ·  Immunoglobulin G (2)  ·  Nivolumab (2)  ·  Specimen Handling (2)  ·  Trifluridine (2)  ·  4-toluenesulfonyl fluoride (1)  ·  Bevacizumab (1)  ·  Capecitabine (1)  ·  Clinical Laboratory Techniques (1)  ·  Cyclophosphamide (1)  ·  Fluorouracil (1)  ·  Gemcitabine (1)  ·  Hydroxychloroquine (1)  ·  Interleukin-2 (1)

Sponsors

M.D. Anderson Cancer Center (4)  ·  Academic and Community Cancer Research United (1)  ·  Emory University (1)  ·  Fudan University (1)  ·  National Cancer Institute (NCI) (1)  ·  Northwestern University (1)  ·  Rutgers, The State University of New Jersey (1)  ·  University of Southern California (1)

Countries

United States (10)  ·  China (1)

Top investigators

Amir A Jazaeri (1)  ·  David S Hong (1)  ·  Devalingam Mahalingam (1)  ·  Heinz-Josef Lenz, MD (1)  ·  Howard S Hochster (1)  ·  Jianmin Xu (1)  ·  Kanwal Raghav (1)  ·  Liza C Villaruz (1)  ·  Niharika Mettu (1)  ·  Olumide B. Gbolahan, MBBS, MSc (1)  ·  Van K Morris, MD (1)

Results publications

PMID 31401903, PMID 33109741, PMID 35179586, PMID 37852737, PMID 38309721, PMID 39886125

NIH funding

P30CA014089 (1), P30CA015083 (1), P30CA060553 (1), P30CA072720 (1), P30CA138292 (1), UM1CA186689 (1), UM1CA186690 (1), UM1CA186704 (1), UM1CA186717 (1)